Interesting to note that at the ASCO 2024 Annual General Meeting in Chicago there are 16 poster sessions and 8 publications that relate to Oncolytic therapies.
https://meetings.asco.org/search?q=...resentations"}]}&pageNumber=1&size=20
Always good to look over the fence to see what others are doing in this space.
However, our onCARlytic therapy is the only one that seeks to express CD19 on the solid tumor cell surface, effectively painting or marking the cancer cells as targets for killing by the combined CAR-T drug, in this case Amgen's blinatumomab aka Blyncyto.
GLTAH - Go Team Imugene
.
Interesting to note that at the ASCO 2024 Annual General Meeting...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.2¢ |
Change
-0.003(3.53%) |
Mkt cap ! $600.2M | |||
| Open | High | Low | Value | Volume |
| 8.5¢ | 8.6¢ | 8.2¢ | $1.246M | 14.84M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 446526 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.3¢ | 535664 | 2 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.2¢ |
Change
-0.003 ( 2.38 %) |
||||
| Open | High | Low | Volume | ||
| 8.6¢ | 8.6¢ | 8.2¢ | 4518456 | ||
| Last updated 15.57pm 03/05/2024 ? | |||||
| IMU (ASX) Chart |